Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study The 6-month discontinuation rates of tamoxifen ...

Although previous studies have been somewhat inconsistent, a new study shows that breast cancer patients taking tamoxifen who have genetic alterations in CYP2D6 have a higher likelihood of both ...

Life-threatening opioid intoxication developed in a patient after he was given small doses of codeine for the treatment of a cough associated with bilateral pneumonia. Codeine is bioactivated by ...

A new in vivo pharmacokinetic recall study involving 114 participants in the Estonian Biobank has provided the first clinical confirmation that previously uncharacterized genetic variants in the ...

The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, has today published consensus recommendations to aid in the design and validation of ...

In recent years, scientists discovered that an enzyme called CYP2D6 could possibly predict whether a patient would respond to the drug. Small studies aimed at confirming the predictive link, however, ...

Aim We sought to discover endogenous urinary biomarkers of human CYP2D6 activity. Patients & Methods Healthy pediatric subjects (n = 189) were phenotyped using dextromethorphan and randomized for ...

A research team led by Associate Professor Shinpei Yamaguchi and the late Professor Masako Tada of the Faculty of Science, together with Professor Yojiro Anzai and Lecturer Yohei Iizaka of the Faculty ...

Accurate prediction of CYP2D6 activity from genotype data is of utmost importance as CYP2D6 pharmacogenetic (PGx) testing is increasingly used to guide drug therapy. However, given the complexity of ...

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study We conducted a prospective-retrospective study ...